Search
for
Sort by
Research 91–120 of 1000+
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Topical Janus kinase inhibitors: A review of applications in dermatology
- Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
- 72751 Janus Kinase Inhibitors for Alopecia Universalis: A Systematic Review
- P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
- The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- The role of janus kinases in the treatment of autoimmune skin diseases
- Use of intramuscular triamcinolone acetonide in intermediate responders to janus kinase inhibition for alopecia areata: Case report
- <i>In‐silico</i> Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its <i>In‐vitro</i> Evaluation
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
- Janus kinase (JAK)
- Inhibiting Janus kinases to treat alopecia areata
- Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- JAK Inhibitors for Treatment of Alopecia Areata
- JAK inhibitors and alopecia areata
- Emerging drugs for alopecia areata: JAK inhibitors
- Under Development JAK Inhibitors for Dermatologic Diseases
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice